Stay updated with breaking news from Efficacy Endpoints. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Cassava Sciences, Inc. announced positive top-line Phase 2 results for simufilam, its oral drug candidate for Alzheimer's disease dementia. This was an open-label safety study with exploratory... | January 25, 2023
/PRNewswire/ -- UCB, a global biopharmaceutical company, today announced that it will present 15 abstracts across its rheumatology portfolio at ACR Convergence...
/PRNewswire/ -- UCB, a global biopharmaceutical company, today announced that it will present 15 abstracts across its rheumatology portfolio at ACR Convergence...
Share this article Share this article INDIANAPOLIS, March 17, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced patient-reported outcomes (PRO) for the investigational use of Verzenio ® (abemaciclib) in combination with standard adjuvant endocrine therapy (ET) for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) high risk early breast cancer (EBC). The PRO analysis included patients in both arms of the study and measured their experiences with side effects, symptoms, and health-related quality of life, in those ...
Synthetic mRNA Covid vaccines: A Risk-Benefit Analysis Published: February 23, 2021 Amidst the plethora of Covid-related issues, the Covid injections are the most imminent. Two formulations have received interim approval from the FDA, and Health Canada: Pfizer/BioNtech and Moderna. Both these injections are employing the same technology, synthetic gene therapy (SGT), which is being dispensed to the populace for the first time in human history. Medications are given to sick people to treat disease. Vaccines are given to healthy people to prevent an infection. Therefore consideration of risk-be...